Abstract The main objective of the study was to analyze the incidence of iron overload (IO) and its management in transfusion-dependent patients with low-risk myelodysplastic syndrome (MDS) before the license of deferasirox. This observational, cross-sectional, and multicenter study was conducted from January to May 2007 in 81 Spanish hospitals. Eligible patients had a low or intermediate-1 risk score and had to have received at least ten units of packed red blood cell (PRBC). Of the 549 patients analyzed, 75% had received more than 20 PRBC units since diagnosis; 14% had IO at diagnosis and 58% at last follow-up. Thirty-eight percent of patients received chelation therapy; of those, 92% were treated with desferrioxamine. Ferritin levels at the start of chelation therapy were higher than 1,000 μg/L in 76% and over 2,500 μg/L in 24% of patients. Of the 202 patients who received some form of chelation therapy, ferritin levels increased from a mean±SD of 1,986±1,398 to 2,480± 1,648 μg/L at last follow-up in 86% (p<0.001). In the remaining 29 patients treated with a minimally effective therapy, ferritin levels did not increase. Of these, only 11 patients received such therapy lasting more than 12 months. In conclusion, most low-risk transfusion-dependent MDS patients develop IO, but only a minority receives a minimally effective and timely iron chelation therapy.
Introduction
Myelodysplastic syndromes (MDS) are a group of clonal disorders characterized by peripheral blood cytopenias, morphologic dysplasia secondary to bone marrow dysfunction, and genetic instability with enhanced risk of developing acute myeloid leukemia [1] . MDS can affect people of any age [2] , although the elderly are particularly vulnerable. Their incidence has been estimated at 3.3 cases per 100,000 people per year, but it may increase to 15-50 cases per 100,000 people per year in patients over the age of 70 years [3] .
At diagnosis, 80% to 85% of the patients with MDS are anemic; around 40% show neutropenia and 30% thrombopenia [1, 4] . Despite the recent progresses in treatment, the standard of care in the community for MDS is best supportive care, with most patients requiring chronic transfusions of packed red blood cell (PRBC) to alleviate symptomatic anemia. One of the major consequences of transfusion therapy is iron overload (IO). Over time, IO evolves into overt organopathy, such as hepatopathy and cardiomyopathy, with the consequent increase in mortality unless an adequate timely and individualized chelation therapy is established [5] [6] [7] [8] . It has been shown that, in patients with refractory anemia, transfusion dependency is associated with shorter survival rates, higher risk of leukemic progression, and a higher mortality related to heart failure and secondary IO [9, 10] . In this regard, a previous study carried out by Malcovati et al. [10] showed that the development of secondary IO significantly affected overall survival and demonstrated a clear relationship between the number of PRBC units transfused and the patient's prognosis. Increased mortality due to secondary IO results from non-transferrin-bound iron-induced production of highly reactive oxygen species, which leads to a significant and extensive liver, heart, and endocrine organ injury, as well as a greater propensity for infection [11] .
In order to achieve safe iron levels in tissues and plasma, published guidelines recommend the use of chelation therapy for the management of MDS patients [12, 13] . According to these guidelines, for patients to be considered candidates for iron chelation therapy, they must be transfusion dependent, have a life expectancy of more than 1 year, and have a stable or increasing serum ferritin level above 1,000 μg/L.
For many years, the outstanding "gold standard" for iron chelation in MDS has been desferrioxamine (DFO), but the inconvenience of prolonged subcutaneous infusion is believed to be a major handicap for the administration of this drug. The magnitude of this problem remains unknown, as no studies specifically addressing the management of IO in MDS patients have been published. Information on this issue is particularly important in the light of the recent availability of a new oral iron chelator.
The main objectives of this study were to describe the IO and chelation therapy patterns in a large series of patients with low-risk MDS who require PRBC transfusion support and to assess the efficacy and limitations of iron chelation therapies available for MDS patients before the licensing of deferasirox. The results obtained might be used in the future as a useful comparison resource to address the impact of this new oral iron chelator in the clinical practice.
Patients and methods

Study design
This was an observational, cross-sectional, noninterventional, and multicenter study conducted over 5 months (January to May 2007) in 81 hospitals throughout Spain that represent 42% of the hospitals belonging to the Spanish National Health Care System. The study was approved by the Institutional Review Board, and it was conducted in accordance with the Helsinki Declaration of the World Medical Association amended in 1975 and subsequent revisions. All patients provided a written informed consent. Data were collected in appropriate case report forms, and confidentiality was maintained across the study.
Study procedures
Eligibility criteria were: (1) MDS patients with a low or intermediate-1 International Prognostic Scoring System (IPSS) risk score or a low Spanish Prognostic Index (SPI) risk score, in those patients in whom cytogenetic studies were not available, (2) patients who had received at least ten PRBC units, and (3) patients who attended a medical consultation in a period of 5 months between January and May 2007.
Variables included in the analysis were: (1) demographics (age and gender), (2) clinical data at diagnosis (date of diagnosis, symptoms, comorbidities, and concomitant diseases), (3) hematological parameters at presentation (hemoglobin [Hb] level, absolute neutrophil and platelet counts, and proportion of blast cells in bone marrow), (4) cytogenetics (conventional karyotype and fluorescence in situ hybridization [FISH] , if available), (5) morphological classification (by IPSS and SPI), (6) treatment received for MDS (erythropoietin, granulocyte colony-stimulating factor, lenalidomide, thalidomide, chemotherapy, and others), (7) data about PRBC transfusion requirements (date of first PRBC transfusion and number of PRBC units administered from diagnosis and during the last 12 months), (8) serum ferritin levels (at diagnosis, at the start of iron chelation therapy, and at last assessment), and (9) data about iron chelation therapy (date of first and last administration of an iron chelating agent, drug/s, dose/s, schedule/s and route/s used, duration of chelation with every drug used, and reason for discontinuation or change in prescription).
Definitions
IO was defined as serum ferritin levels above 1,000 μg/L. Minimally effective chelation treatment with DFO was defined as having received at least a daily dose of 25 mg/kg or 2 g for at least 3 days a week.
Statistical analysis
Continuous variables were described using mean, median, standard deviation, and minimum and maximum values and were compared using analysis of variance (ANOVA). Frequency distributions of discrete variables were compared using chi-squared test or Fisher's exact test as appropriate. Significance level was set at p<0.05. Statistical analysis was performed using the statistical software program SPSS® version 13.0
Results
Baseline patient characteristics
Of the 626 MDS patients initially selected to participate in this study, 549 (88%) were finally analyzed. Sixty-two (10.0%) patients were excluded because they did not meet the protocol pre-established eligibility criteria, nine (1.0%) because they had serum ferritin levels lower than 50 μg/L, which could indicate a possible concomitant iron deficiency anemia, four (0.6%) due to the lack of clinical data, and two (0.3%) because the bone marrow study was inadequate to support the diagnosis of MDS.
The main characteristics of the 549 patients included in the study are shown in Table 1 . Median age was 77 years (range 31-97) with half of the patients (51%) belonging to the 66-79 age group. The median Hb level at diagnosis was 90 g/L (35-138 g/L). Twenty-five percent of the patients had an Hb level lower than 80 g/L. Neutropenia and thrombocytopenia were observed at diagnosis in 27% and 11% of the patients, respectively. Successful bone marrow karyotyping was available in 67% of the patients. FISH was carried out in 12% of the patients. Most patients (66%) reported fatigue as the main initial complaint. A high proportion of patients had a previous history of heart disease (30%), vascular disease (29%), and/or endocrine, nutritional, or metabolic disorders (28%). Tables 2, 3 , 4, and 5 show the characteristics of the patients according to the WHO and FAB classifications, as well as IPSS and SPI prognostic indexes. The most frequent morphological diagnosis was refractory anemia with ringed sideroblasts (RARS) followed by refractory anemia (RA), which were observed in 34% and 24% of the patients, respectively. According to the IPSS, 62% and 38% of the patients had low and intermediate-1 risk, respectively. The treatments received for the management of MDS, including growth factors, chemotherapy, and other drugs, are shown in Table 6 . 
Iron overload and chelation treatment
Median serum ferritin level at diagnosis was 408 μg/L (range 120-7,339). Sixty-eight (14%) patients had serum ferritin levels between 1,000 and 2,499 μg/L, and nine (2%) patients had serum ferritin levels greater than 2,500 μg/L. Overall, 202 out of 536 (38%) patients with low-risk MDS received chelation therapy. Of these, 154 (76%) patients had baseline ferritin levels greater than 1,000 μg/L and 48 (24%) patients had ferritin levels greater than 2,500 μg/L. The average serum ferritin level at the beginning of treatment was 1,986±1,398 μg/L. Time from diagnosis to the start of chelation therapy was after (a) five or more years in 55% of patients, (b) 2 to 5 years in 34% of patients, and (c) less than 2 years in 21% of patients. In patients who had developed IO (14%), 92% of those aged 65 years or less and with serum ferritin levels greater than 1,000 μg/L received DFO therapy; this percentage decreased to 52% in patients with ages between 66 and 79 years and to 32% in patients aged 80 years or more.
Of the 202 patients who received chelation therapy, DFO was used in 93% (n=188) of the patients. However, only 29 (14%) patients received a minimally effective dose of DFO and only in 11 patients was DFO administered for more than 12 months.
Serum ferritin levels in the 334 (62%) patients who did not receive any type of chelation therapy significantly increased from 512±615 μg/L at diagnosis to 1,633± 1,401 μg/L at last follow-up (p<0.001). The last ferritin level recorded in this group showed that 152 (46%) of these patients had already developed IO. Of the 202 patients who received some kind of chelation therapy, either minimally effective or not, serum ferritin levels significantly increased from 1,986±1,398 μg/L at the start of treatment to 2,481± 1,648 at the last assessment (p=0.001). However, in patients who received a minimally effective chelation therapy (n=29), serum ferritin levels did not increase over time (from 2,037±1,304 μg/L at the start of treatment to 1,798±1,459 μg/L at the last follow-up; Fig. 1 ). No significant differences were observed regarding changes in serum ferritin levels and patient's age, type of MDS anemia, or use of chelation therapy.
Discussion
The results obtained in the current study show that, in the year 2007, when DFO was the only drug licensed for iron chelation in MDS, only a minority of patients with low-risk RARS  188  34  13  17  96  34  79  41  RA  133  24  16  21  69  25  48  25  RCMD  69  13  11  15  40  14 [10] , and, in most cases, the dosage used was not considered minimally effective to achieve an adequate control of IO. According to the group of Malcovati et al. [7, 10] , ferritin levels of 1,000 μg/L are reached when patients are transfused a median of 21 PRBC units. They have also shown that patient survival is adversely affected as transfusions increase due to a greater risk of developing IO and secondary hemochromatosis [7, 10] . In a retrospective analysis of 46 MDS patients who had received more than 50 units of PRBC during the course of the disease, 20 patients developed heart failure; 11 suffered from hepatopathy; five developed diabetes mellitus, and 14 patients died from refractory congestive heart failure related with IO [14] . Besides IO-related clinical complications, a number of different factors may contribute to the negative effect of transfusion dependency on survival, including more severe disease (higher risk of leukemic progression) and more severe anemia (higher mortality due to heart failure) [7, 9, 15] . Based on these facts, during the recent years, iron chelation is being recommended for low-risk MDS patients with transfusion requirements [13, 16] . Given that the majority of patients in this study were classified as having RARS, RA, or refractory cytopenias with multilineage dysplasia and had received a median of 22 PRBC units during the last year, they would potentially benefit from iron chelation therapy according to the current guidelines [16] .
One of the most significant results of this study was that only 37% of patients were treated with chelation therapy, despite the fact that the majority of them had clinical indications for receiving it. This underscores the importance of taking into consideration not only ferritin levels but also the number PRBC units transfused. Several reasons might have influenced the physicians' decision to delay or to avoid chelation therapy and include the high rate of dropouts due to DFO intolerance, a potential lack of awareness of the benefits of a timely chelation therapy, and the patient's age. In this regard, in patients with ferritin levels greater than 1,000 μg/L, only 32% of patients aged ≥80 years received chelation with DFO versus 92% of patients aged ≤65 years. These results show that chelation therapy was started, in spite of DFO intolerance, in the youngest MDS patients with IO. Age is an important factor to take into account when making the decision to start chelation therapy since MDS patients who have a short Total (n=369) Prognosis according to karyotype Low  229  62  219  67  8  20  0  0  Intermediate-1  140  38  108  33  33  80  1  100  Intermediate-2 GCSF growth colony-stimulating factor a One or more than one expected survival will probably not benefit from such treatment [17] . The fact that, until recently, iron chelation treatment recommendations in MDS were based on limited data further complicates the picture (evidence grade B, level III) [18] . Nowadays, several comparative studies have shown that mortality is higher in heavily iron-overloaded patients [19, 20] and that chelation treatment seems to improve survival in MDS patients [16, 21] . The guidelines published to date regarding IO treatment agree that iron chelation therapy is indicated in patients with a ferritin level of 1,000 μg/L or more and/or who have received a transfusion of two units per month of PRBC for at least 1 year [16, 21] . In contrast, iron chelation should not be offered to patients with an anticipated survival of less than 1 year [16] . From our results, it seems that iron chelation therapy was started too late since 76% of the patients had ferritin levels above 1,000 μg/L and 24% had ferritin levels above 2,500 μg/L at the start of chelation therapy. In addition, chelation therapy was administered only to half of the MDS patients when five or more years had elapsed since diagnosis.
Another interesting observation was that only a minority of the patients exposed to chelation therapy received a minimally effective chelation treatment with DFO. This result might reflect the low compliance rate in MDS patients treated with DFO, which is probably related to its administration schedule, as it has been previously described in a Spanish prospective study [22] . Also, our results showed that ferritin levels increased in patients who received inadequate chelation therapy. In contrast, in patients who received a minimally effective dose of DFO, ferritin levels were stabilized and did not increase in spite of the transfusions received. These results reinforce the assumption that chelation therapy must be included in guidelines designed for the treatment of MDS patients.
The results of this observational study should be interpreted in the light of potential limitations, which reside mainly in the lack of randomization and blindness inherent to the study's design. Nevertheless, this study has shown that, despite the fact that there is scientific evidence to support chelation therapy in MDS patients with transfusion requirements, chelation is not as widely used as it should, except perhaps in the youngest population, probably due, in part, to the fact that, at the time of this study, DFO was the only iron chelator licensed for use in patients with MDS who are transfusion dependent. Also, single measurements of ferritin levels have limitations and should not be the only factor to consider when assessing IO and chelation therapy efficacy [23] . However, repeated serum ferritin level measurements are currently the most widely used monitoring technique, partly due to its wide availability, noninvasive nature, and inexpensiveness and due to the fact that there is no optimal test for this purpose [12, 24] . In summary, in this group of MDS patients with transfusion requirements, it seems that patients with IO were undertreated, as chelation therapy was started late and was not administered rigorously enough. Nowadays, MDS patients live longer and receive more PRBC transfusions, and, consequently, physicians should be aware of the potential organ damage related to iron accumulation in order to prevent it or treat it.
